A5048713177- Cancer Cells and Metastasis
- Cervical Cancer and HPV Research
- Cancer-related Molecular Pathways
- Cell Adhesion Molecules Research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Protease and Inhibitor Mechanisms
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Poxvirus research and outbreaks
- Cancer Treatment and Pharmacology
- Nonmelanoma Skin Cancer Studies
- Herpesvirus Infections and Treatments
- Cytokine Signaling Pathways and Interactions
- Monoclonal and Polyclonal Antibodies Research
- NF-κB Signaling Pathways
- Immune Response and Inflammation
- Genomics and Chromatin Dynamics
- Virus-based gene therapy research
- Mechanisms of cancer metastasis
- Cancer Immunotherapy and Biomarkers
- Microtubule and mitosis dynamics
- Infectious Diseases and Mycology
- Breast Lesions and Carcinomas
- Cardiac Ischemia and Reperfusion
University Hospital Centre Zagreb
2009-2024
University of Zagreb
2011-2024
Mitochondria are involved in crucial homeostatic processes the cell: production of adenosine triphosphate and reactive oxygen species, release pro-apoptotic molecules. Thus, cell survival depends on maintenance proper mitochondrial function by quality control. The most important control mechanisms unfolded protein response, mitophagy, biogenesis, fusion-fission dynamics. This review deals with heart diseases, especially myocardial infarction failure. Some previous studies have demonstrated...
Urokinase-type plasminogen activator (uPA) and inhibitor (PAI-1) are key molecules in pericellular proteolysis, a process that plays an important role tumor invasion metastasis. In the current study we investigated prognostic significance of uPA PAI-1 primary invasive breast cancer.uPA antigen levels were determined by enzyme-linked immunosorbent assay cytosols 177 ductal carcinoma specimens. The was assessed for overall survival. median follow-up time 90 months.In univariate analysis, both...
e13080 Background: The combination of CDK4/6i and endocrine therapy (ET) is the standard care in first-line treatment hormone receptor positive (HR+), HER2- aBC. In registrational studies, progression-free survival (PFS) all three ranged from 23.8 to 28.12 months overall (OS) 53.9 66.8. Croatia, both ribociclib palbociclib were approved for clinical use August 2018 abemaciclib November 2019. Methods: This retrospective study included patients with endocrine-sensitive HR+, aBC treated...
Urokinase-type plasminogen activator (uPA) and inhibitor (PAI-1) are key molecules in pericellular proteolysis, a process that plays an important role tumor invasion metastasis. In the current study we investigated prognostic significance of uPA PAI-1 primary invasive breast cancer.uPA antigen levels were determined by enzyme-linked immunosorbent assay cytosols 177 ductal carcinoma specimens. The was assessed for overall survival. median follow-up time 90 months.In univariate analysis, both...
In this study we investigated the prognostic significance of serum matrix metalloproteinase (MMP)-1 levels in early-stage breast cancer patients and correlated these with various clinicopathologic parameters. MMP-1 were determined by enzyme-linked immunosorbent assay. (n = 60) significantly lower than healthy subjects 20, p < 0.0001). We found significant negative correlation between several factors cancer. Kaplan–Meier analysis showed shorter 5-year survival values compared to those high (p...
Apoptosis inhibition is a major tumorigenic factor. Bcl-2 dysregulation and TP53 mutation status, which may correlate with autoantibody generation, contribute to impaired apoptosis.This study aimed investigate the prognostic value of circulating anti-p53 antibodies (p53Abs) in 17.5-year follow-up breast cancer patients. We also analyzed correlations p53Abs various clinicopathological parameters order assess their impact on tumor aggressiveness.Serum levels were by enzyme-linked immunosorbent...
Abstract Introduction Breast cancer (BC) is a disease characterized by significant intra- and intertumoral heterogeneity. Hence, it not surprising that new subtypes with distinct biological features are being discovered, even among previously well-defined BC groups. Recently, HER2-low emerged as entity specific clinical behavior, response to treatment prognosis. subset of HER2-negative BC, HER2 immunohistochemical (IHC) score 1+ or 2+, without gene amplification measured in situ...